Clinical trial
Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor…
NCT00463788 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00463788 |
|---|---|
| Title | Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer |
| Official title | Randomized Phase II Trial With Cetuximab and Cisplatin in the Treatment of ER-negative, PgR-negative, HER2-negative Metastatic Breast Carcinoma ("Basal Like") |
| Acronym | BALI-1 |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasm |
| Intervention type | Drug |
| Interventions | cetuximab, cisplatin |
| Enrollment | 181 |
| Start date | Jun 1, 2007 |
| Primary completion | Jul 1, 2009 |
| Completion | Feb 1, 2011 |
| First posted | Apr 20, 2007 |
| Last update posted | Feb 13, 2014 |
| Countries | Australia, Austria, Belgium, Germany, Ireland, Israel, Italy, New Zealand, Portugal, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: